Proleukin(R) Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Trial Profile

Proleukin(R) Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms PROCLAIM
  • Sponsors Prometheus Laboratories
  • Most Recent Events

    • 06 Jun 2017 Results (n=1457) assessing association of overall survival and tumor control with development of immune-related events in patients treated with IL2, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 10 Feb 2017 Planned End Date changed from 1 Aug 2016 to 1 Aug 2020.
    • 10 Feb 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top